Vicriviroc maleate

Vicriviroc maleate (CAS No.: 599179-03-0) is a potent and selective CCR5 receptor antagonist, structurally based on piperazine, and recognized for its significant role in biomedical research contexts, particularly in the arena of drug discovery targeting viral infections. As a molecule that can traverse the blood-brain barrier, Vicriviroc maleate is particularly notable for its capacity to inhibit HIV-1 activity in peripheral blood mononuclear cells, demonstrating IC90 values ranging from nanomolar to low micromolar levels, with specific measurements such as 3.3 nM against the JrFL strain and 2.8 nM against ADA-M. Its efficacy across various strains highlights its utility in mechanistic studies of CCR5-mediated pathways. The compound operates by obstructing the interaction between HIV-1 and CCR5 receptors, effectively disrupting the viral entry process. In vitro experiments have underscored its activity with an IC50 value of approximately 0.91 nM, illustrating its promising inhibitory potential. Research applications in cell-based assays often explore its effects using concentrations tailored to the study design and research goals. The compound's impact is further investigated in preclinical models and drug screening programs to elucidate its influence on CCR5 signaling pathways, providing insights into viral pathogenesis and potential intervention strategies. Through a comprehensive examination of its inhibitory characteristics, Vicriviroc maleate stands as a critical tool in the study of viral entry mechanisms and receptor-ligand interactions within the field of infectious disease research.